CpG motifs as possible adjuvants for the treatment of allergic diseases.
DNA containing unmethylated CpG motifs and synthetic oligodeoxynucleotides derived thereof (CpG ODN) have intensively been investigated for their immunostimulatory properties in the recent past. CpG ODN were shown to induce strong Th1 immune responses in mammals. The downregulation of the antigen-driven Th2 response of type I allergies represents one important therapeutic goal of specific immunotherapy (SIT). Hence, CpG ODN represent promising substances which support the modification of the pathogenic Th2 immune profile toward a Th1 profile when used as adjuvants for SIT. This article discusses how the use of CpG ODN in immunotherapeutics could improve the treatment of type I allergy.
Bohle
Barbara
B
Department of Pathophysiology, Division of Immunopathology, University of Vienna, Austria. barbara.bohle@akh-wien.ac.at
D000276:Adjuvants, Immunologic / Q000494:pharmacology* / Q000627:therapeutic use*; D000818:Animals; D016207:Cytokines / Q000187:drug effects / Q000276:immunology; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy*; D007073:Immunoglobulin E / Q000187:drug effects / Q000276:immunology; D009838:Oligodeoxyribonucleotides / Q000494:pharmacology* / Q000627:therapeutic use*; D037182:T-Cell Antigen Receptor Specificity / Q000187:drug effects / Q000276:immunology; D016176:T-Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology; D006377:T-Lymphocytes, Helper-Inducer / Q000187:drug effects / Q000276:immunology
D000276:Adjuvants, Immunologic; C408982:CPG-oligonucleotide; D016207:Cytokines; D009838:Oligodeoxyribonucleotides; D007073:Immunoglobulin E